SK284477B6 - Šumivé formulácie a spôsob ich výroby - Google Patents

Šumivé formulácie a spôsob ich výroby Download PDF

Info

Publication number
SK284477B6
SK284477B6 SK1432-2000A SK14322000A SK284477B6 SK 284477 B6 SK284477 B6 SK 284477B6 SK 14322000 A SK14322000 A SK 14322000A SK 284477 B6 SK284477 B6 SK 284477B6
Authority
SK
Slovakia
Prior art keywords
effervescent
formulations according
effervescent formulations
alkali
citric acid
Prior art date
Application number
SK1432-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK14322000A3 (sk
Inventor
Wolfram Tritthart
Mario Andr Piskernig
Gottfried K�Lbl
Original Assignee
Viatris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh & Co. Kg filed Critical Viatris Gmbh & Co. Kg
Publication of SK14322000A3 publication Critical patent/SK14322000A3/sk
Publication of SK284477B6 publication Critical patent/SK284477B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
SK1432-2000A 1998-03-31 1999-03-20 Šumivé formulácie a spôsob ich výroby SK284477B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen
PCT/DE1999/000798 WO1999049842A1 (de) 1998-03-31 1999-03-20 Brauseformulierungen

Publications (2)

Publication Number Publication Date
SK14322000A3 SK14322000A3 (sk) 2001-07-10
SK284477B6 true SK284477B6 (sk) 2005-04-01

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1432-2000A SK284477B6 (sk) 1998-03-31 1999-03-20 Šumivé formulácie a spôsob ich výroby

Country Status (29)

Country Link
US (1) US6242002B1 (ko)
EP (1) EP1067905B1 (ko)
JP (1) JP4469494B2 (ko)
KR (1) KR100607395B1 (ko)
CN (1) CN1138529C (ko)
AR (1) AR018829A1 (ko)
AT (1) ATE224703T1 (ko)
AU (1) AU753194B2 (ko)
BG (1) BG65043B1 (ko)
BR (1) BR9909266A (ko)
CA (1) CA2326502C (ko)
CZ (1) CZ300705B6 (ko)
DE (2) DE19814257A1 (ko)
DK (1) DK1067905T3 (ko)
ES (1) ES2183555T3 (ko)
HK (1) HK1036010A1 (ko)
HU (1) HU229793B1 (ko)
IL (1) IL138605A (ko)
NO (1) NO329143B1 (ko)
NZ (1) NZ506989A (ko)
PL (1) PL192049B1 (ko)
PT (1) PT1067905E (ko)
RU (1) RU2221554C2 (ko)
SK (1) SK284477B6 (ko)
TR (1) TR200002812T2 (ko)
TW (1) TW580398B (ko)
UA (1) UA66847C2 (ko)
WO (1) WO1999049842A1 (ko)
ZA (1) ZA200005133B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
US7862833B2 (en) * 2003-12-31 2011-01-04 Cima Labs, Inc. Effervescent oral opiate dosage forms and methods of administering opiates
NZ548216A (en) 2003-12-31 2010-02-26 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US7033511B2 (en) * 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
JP5209966B2 (ja) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2629904C (en) * 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
AU2009303979A1 (en) * 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9560870B2 (en) 2012-02-01 2017-02-07 Intercontinental Great Brands Llc Low calorie drink tablet
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
CN115551982A (zh) * 2020-05-28 2022-12-30 联合利华知识产权控股有限公司 片剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
EP0521388B1 (de) 1991-07-01 1995-05-10 Gerhard Dr. Gergely Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
US5415870A (en) * 1991-07-01 1995-05-16 Gerhard Gergely Effervescent systems using reaction doping agents
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
WO1994000124A1 (en) 1992-06-22 1994-01-06 Eckard Weber Glycine receptor antagonists and the use thereof
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
WO1994017792A2 (en) 1993-01-27 1994-08-18 Affymax Technologies N.V. Compositions and methods for transdermal drug delivery
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
DE59400446D1 (de) * 1993-04-15 1996-08-29 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen Wirkstoff, und Verfahren zur Herstellung
US5683711A (en) 1993-04-20 1997-11-04 Hexal Pharma Gmbh Active ingredient patch
US5503844A (en) 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
US5759575A (en) 1993-09-09 1998-06-02 Gerhard Gergely Effervescent granules and process for their preparation
WO1995013130A1 (de) 1993-11-12 1995-05-18 Gerhard Gergely Verfahren zum herstellen von granulat
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau Reinhard Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
AU707646B2 (en) 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
TW580398B (en) 2004-03-21
CA2326502C (en) 2008-08-05
PL343260A1 (en) 2001-07-30
AR018829A1 (es) 2001-12-12
PL192049B1 (pl) 2006-08-31
NZ506989A (en) 2002-09-27
CZ300705B6 (cs) 2009-07-22
CZ20003482A3 (en) 2001-05-16
ES2183555T3 (es) 2003-03-16
HU229793B1 (en) 2014-07-28
AU4029499A (en) 1999-10-18
WO1999049842A1 (de) 1999-10-07
NO20004721L (no) 2000-09-21
HUP0101427A3 (en) 2001-12-28
TR200002812T2 (tr) 2001-01-22
DK1067905T3 (da) 2003-02-03
HK1036010A1 (en) 2001-12-21
EP1067905B1 (de) 2002-09-25
CN1295463A (zh) 2001-05-16
SK14322000A3 (sk) 2001-07-10
UA66847C2 (uk) 2004-06-15
CN1138529C (zh) 2004-02-18
HUP0101427A2 (hu) 2001-08-28
IL138605A0 (en) 2001-10-31
AU753194B2 (en) 2002-10-10
US6242002B1 (en) 2001-06-05
JP2002509872A (ja) 2002-04-02
DE19814257A1 (de) 1999-10-07
IL138605A (en) 2005-11-20
RU2221554C2 (ru) 2004-01-20
EP1067905A1 (de) 2001-01-17
KR20010042317A (ko) 2001-05-25
BG65043B1 (bg) 2007-01-31
PT1067905E (pt) 2003-02-28
ZA200005133B (en) 2001-02-28
JP4469494B2 (ja) 2010-05-26
CA2326502A1 (en) 1999-10-07
BG104841A (en) 2001-07-31
BR9909266A (pt) 2000-11-21
NO329143B1 (no) 2010-08-30
DE59902843D1 (de) 2002-10-31
KR100607395B1 (ko) 2006-08-02
ATE224703T1 (de) 2002-10-15
NO20004721D0 (no) 2000-09-21

Similar Documents

Publication Publication Date Title
SK284477B6 (sk) Šumivé formulácie a spôsob ich výroby
EP1008354B1 (en) Immediately disintegrable medicinal compositions
RU2648760C2 (ru) Фармацевтическая композиция, содержащая оксигидроксид железа, способ ее получения и применение
FI109453B (fi) Farmaseuttinen koostumus
RU2481110C2 (ru) Лекарственные формы с улучшенными фармакокинетическими свойствами
JP2006524650A (ja) 口腔内崩壊錠
SK283633B6 (sk) Farmaceutický prípravok obsahujúci ACE inhibítor ramipril a dihydropyridínovú zlúčeninu, spôsob výroby farmaceutického prípravku a jeho použitie
US20030077321A1 (en) Process for preparing tannate tablet, capsule or other solid dosage forms
SK281779B6 (sk) Tabletky tramadolu alebo tramadolovej soli
EP2377522A1 (en) Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
WO2012113894A1 (en) Pharmaceutical combination of betahistine and trimetazidine
US20150072014A1 (en) Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid
PL200858B1 (pl) Jednostka dawkowania do podawania doustnie zawierająca mirtazapinę
SK16799A3 (en) Granulates comprising a water soluble compound and cellulose
MXPA00009396A (en) Fizzy formulations
KR100307251B1 (ko) 아시클로버 확산정의 조성물 및 그의 제조방법
KR100329685B1 (ko) 아세트아미노펜 확산정의 조성물 및 그의 제조방법
WO2013115741A1 (en) Pharmaceutical compositions comprising alpha-glucosidase inhibitor
NZ243613A (en) Tablet comprising praziquantel, pyrantel pamoate and oxantel pamoate in synergistic proportions for treatment of nematode infestations

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20170320